Tenaya Therapeutics Announces Closing of Public Offering
November 21 2022 - 5:45PM
Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage
biotechnology company with a mission to discover, develop and
deliver potentially curative therapies that address the underlying
causes of heart disease, announced today the closing of its
previously announced underwritten public offering of 22,613,307
shares of its common stock and, to certain investors in lieu of
common stock, pre-funded warrants to purchase up to an aggregate of
6,236,693 shares of its common stock. The aggregate gross proceeds
from the offering were $75.0 million before deducting underwriting
discounts and commissions and offering expenses payable by Tenaya.
All of the shares and pre-funded warrants were sold by Tenaya.
Tenaya has also granted the underwriters a 30-day option to
purchase up to an additional 4,327,500 shares of its common stock.
Morgan Stanley and Piper Sandler acted as joint book-running
managers for the offering. H.C. Wainwright & Co. and Chardan
acted as co-lead managers for the offering.
The offering was made pursuant to a Registration Statement on
Form S-3, which was declared effective by the SEC, and the final
prospectus supplement relating to the offering which was filed with
the SEC. These documents can be accessed for free through the SEC’s
website at www.sec.gov or by request from: Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, NY 10014; or Piper Sandler & Co., 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus
Department, by telephone at (800) 747-3924, or by email at
prospectus@psc.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or other jurisdiction in which such
offer, solicitation, or sale would be unlawful before registration
or qualification under the securities laws of that state or
jurisdiction.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company
committed to a bold mission: to discover, develop and deliver
curative therapies that address the underlying drivers of heart
disease. Founded by leading cardiovascular scientists from
Gladstone Institutes and the University of Texas Southwestern
Medical Center, Tenaya is developing therapies for rare
genetic cardiovascular disorders as well as for more prevalent
heart conditions through three distinct but interrelated product
platforms: Gene Therapy, Cellular Regeneration and Precision
Medicine.
Contact
Michelle CorralVice President, Investor Relations and Corporate
CommunicationsTenaya TherapeuticsIR@tenayathera.com
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Jul 2023 to Jul 2024